GLP1R and type 2 diabetes mellitus: Semaglutide reduces weight, glucose levels, and CV risk in individuals with T2DM. Preclinical studies with a mechanical approach indicate that weight loss occurs due to the brain’s activation of GLP-1 receptors (GLP-1 Rs). The results presented in this context demonstrate that semaglutide altered food preferences, decreased food consumption, and caused weight loss without reducing energy expenditure.